Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth

Dateline City: WHITEHOUSE STATION, N.J. Post-partum Hemorrhage Is Leading Cause of Mothers Dying WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ferring Pharmaceuticals today announced their collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV). Language: English Contact: MerckMedia:Jennifer Allen Woodruff, 267-305- 3550orLainie Keller, 908-423-4187orInvestor:Carol Ferguson, 908-423-4465orFerring Media:Helen Gallagher, +41 58 301 0051orPatrick Gorman, +41 58 301 0053 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news